ClearPath Vaccines

ClearPath Vaccines was a private vaccine development company and subsidiary of ClearPath Development focused on novel prophylactic vaccines for infectious diseases with high unmet medical need. The company worked closely with Astellas Pharma under a strategic partnership intended to build a vaccine portfolio, and it pursued vaccines targeting healthcare-associated and other serious bacterial infections. Publicly disclosed work included a Staphylococcus aureus vaccine collaboration using Boston Children's Hospital's MAPS technology, alongside related nosocomial vaccine efforts connected to Affinivax and academic collaborators. Available public information suggests its programs were in preclinical research rather than human clinical development. The company appears to have operated as a specialized vaccine vehicle rather than a broad commercial biopharma organization.